Biogen is set to acquire RayThera in a deal valued at up to $1 billion, according to reports from Yahoo Finance and Seeking Alpha. The transaction would involve Biogen purchasing RayThera, with the total consideration structured to reach a maximum of $1 billion, implying that the final price depends on deal terms that may include milestones or other contingent factors. Both sources describe the acquisition as a significant corporate development for Biogen, positioning the company to add RayThera’s assets and capabilities. The reporting does not provide additional detailed terms such as the upfront amount versus potential earn-outs, nor does it specify timing, regulatory steps, or expected closing conditions within the provided excerpts. Overall, the coverage is aligned on the core announcement: Biogen agreed to acquire RayThera and the deal is valued at up to $1 billion.